Kerwin, Edward M.
Ferguson, Gary T.
Mo, Mindy
DeAngelis, Kiernan
Dorinsky, Paul
Funding for this research was provided by:
Pearl – a member of the AstraZeneca Group (N/A)
Article History
Received: 23 May 2019
Accepted: 4 July 2019
First Online: 29 July 2019
Ethics approval and consent to participate
: The informed consent form and study protocol were approved by an institutional review board (Schulman Associates; approval number 201503097), and patients provided written informed consent for both KRONOS and the extension study prior to screening.
: Not applicable.
: EMK has served on advisory boards, speaker panels or received travel reimbursement from Amphastar, AstraZeneca, Boehringer Ingelheim, Cipla, Forest, GlaxoSmithKline, Mylan, Novartis, Oriel, Pearl – a member of the AstraZeneca Group, Sunovion, Teva, and Theravance. He has conducted multicenter clinical trials for ~ 40 pharmaceutical companies. GTF reports grants, personal fees, and non-financial support from AstraZeneca during the conduct of the study; grants, personal fees, and non-financial support from AstraZeneca, Boehringer Ingelheim, Novartis, Pearl – a member of the AstraZeneca Group, and Sunovion; grants and personal fees from Theravance; and personal fees from Circassia, GlaxoSmithKline, Innoviva, Mylan, and Verona, outside the submitted work. MM, KDeA, and PD are employees of Pearl – a member of the AstraZeneca Group.